Findings

What do systematic reviews say?

358 questions · 360 findings · 31 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 86 · 23.9%GRADE not reported 15 · 4.2%Very low 40 · 11.1%Low 117 · 32.5%Moderate 90 · 25%High 12 · 3.3%

Selective serotonin reuptake inhibitors vs placebo

RCS · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nitrate/nitrate derivatives vs placebo

Migraine frequency Number of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 86 participants
Very low

Nitrate/nitrate derivatives vs placebo

Severity of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Very low

Nitrate/nitrate derivatives vs placebo

Duration of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 77 participants
GRADE not reported

Nitrate/nitrate derivatives vs placebo

QoL · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nitrate/nitrate derivatives vs placebo

Adverse events (3 weeks' · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 8 participants
GRADE not reported

Nitrate/nitrate derivatives vs placebo

RCS · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 69 participants
Low

Phosphodiesterase inhibitors vs placebo

Migraine frequency Number of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 111 participants
Low

Phosphodiesterase inhibitors vs placebo

Severity of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 111 participants
Very low

Phosphodiesterase inhibitors vs placebo

Duration of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Low

Angiotensin‐converting enzyme inhibitors vs placebo

QoL · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Phosphodiesterase inhibitors vs placebo

QoL · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Phosphodiesterase inhibitors vs placebo

Adverse events · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 138 participants
GRADE not reported

Phosphodiesterase inhibitors vs placebo

RCS · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 79 participants
Low

Angiotensin‐converting enzyme inhibitors vs placebo

Adverse events (4 to 6‐week · primary Raynaud's phenomenon

Angiotensin‐converting enzyme inhibitors showed no clear difference in adverse events (4 to 6‐week compared with placebo (low certainty).

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
RR 1.35 [0.67, 2.73]
3 studies · 46 participants
Low

Angiotensin‐converting enzyme inhibitors vs placebo

RCS · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Alpha‐blockers vs placebo

Migraine frequency Number of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
GRADE not reported

Alpha‐blockers vs placebo

Severity of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
GRADE not reported

Alpha‐blockers vs placebo

Duration of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
GRADE not reported

Compression stockings vs no treatment or placebo stockings

Change in symptoms (ranging from 1 week to 3 months) · people with varicose veins without venous ulceration

1 finding from 1 review

Graduated compression stockings for the initial treatment of varicose veins in people without venous ulceration 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 232 participants
Low